H.C. Wainwright analyst Swayampakula Ramakanth has maintained their bullish stance on DCTH stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Swayampakula Ramakanth has given his Buy rating due to a combination of factors, primarily driven by the robust performance and adoption of Delcath Systems’ HEPZATO product. The company reported significant revenue growth in the second quarter of 2025, largely attributed to HEPZATO’s sales, which saw a substantial year-over-year increase. This growth is supported by the activation of multiple treatment centers and plans for further expansion, indicating a strong market presence and potential for continued revenue increase.
Furthermore, Delcath’s participation in the Medicaid National Drug Rebate Agreement is expected to enhance treatment volumes, despite a potential short-term reduction in revenue per kit due to discounted pricing. The company’s strategic regional expansion and upcoming Phase 2 studies for HEPZATO in treating liver-dominant metastatic cancers are anticipated to significantly broaden its market, offering promising long-term growth prospects. These factors collectively underpin the Buy rating and the raised price target of $31 per share.
Ramakanth covers the Healthcare sector, focusing on stocks such as Ocugen, Delcath Systems, and Corcept Therapeutics. According to TipRanks, Ramakanth has an average return of 6.8% and a 38.72% success rate on recommended stocks.
In another report released yesterday, Clear Street also maintained a Buy rating on the stock with a $27.00 price target.